Yanan Zhu
Stock Analyst at Wells Fargo
(0.77)
# 3,657
Out of 4,711 analysts
59
Total ratings
22.22%
Success rate
-17.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AFMD Affimed | Maintains: Overweight | $20 → $15 | $1.19 | +1,160.50% | 6 | Dec 12, 2024 | |
| EDIT Editas Medicine | Downgrades: Equal-Weight | $7 → $4 | $1.31 | +205.34% | 6 | Dec 11, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $80 → $70 | $12.18 | +474.71% | 2 | Nov 18, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $17 → $4 | $0.83 | +384.61% | 4 | Nov 12, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $77 | $35.63 | +116.11% | 2 | Nov 7, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $60 → $40 | $8.50 | +370.59% | 7 | Sep 25, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $35 → $40 | $23.86 | +67.64% | 2 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $70 → $65 | $40.72 | +59.63% | 1 | May 9, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $30 | $5.83 | +414.58% | 1 | Apr 22, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $58 | $15.48 | +274.68% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $4.05 | +517.28% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $7.38 | +238.75% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $31.82 | +57.13% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $14 | $5.75 | +143.48% | 1 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.68 | +197.62% | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.47 | +61.94% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.96 | +22,859.18% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $8 | $2.29 | +249.34% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $29.01 | +261.94% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.85 | +440.54% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $3 | $0.60 | +395.95% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $34 → $24 | $16.98 | +41.34% | 1 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $623.82 | -47.74% | 1 | Feb 2, 2021 |
Affimed
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $1.19
Upside: +1,160.50%
Editas Medicine
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.31
Upside: +205.34%
Intellia Therapeutics
Nov 18, 2024
Maintains: Overweight
Price Target: $80 → $70
Current: $12.18
Upside: +474.71%
RAPT Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $0.83
Upside: +384.61%
Ionis Pharmaceuticals
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $35.63
Upside: +116.11%
bluebird bio
Sep 25, 2024
Maintains: Equal-Weight
Price Target: $60 → $40
Current: $8.50
Upside: +370.59%
Spyre Therapeutics
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $23.86
Upside: +67.64%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $40.72
Upside: +59.63%
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $5.83
Upside: +414.58%
Arcturus Therapeutics Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $45 → $58
Current: $15.48
Upside: +274.68%
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $4.05
Upside: +517.28%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $7.38
Upside: +238.75%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $31.82
Upside: +57.13%
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $5.75
Upside: +143.48%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.68
Upside: +197.62%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $2.47
Upside: +61.94%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $1.96
Upside: +22,859.18%
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $2.29
Upside: +249.34%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $29.01
Upside: +261.94%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.85
Upside: +440.54%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $0.60
Upside: +395.95%
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $16.98
Upside: +41.34%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $623.82
Upside: -47.74%